BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 18755556)

  • 1. Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.
    Rodríguez N; Algara M; Foro P; Lacruz M; Reig A; Membrive I; Lozano J; López JL; Quera J; Fernández-Velilla E; Sanz X
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):810-7. PubMed ID: 18755556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-volumetric parameters of acute esophageal toxicity in patients with lung cancer treated with three-dimensional conformal radiotherapy.
    Kim TH; Cho KH; Pyo HR; Lee JS; Han JY; Zo JI; Lee JM; Hong EK; Choi IJ; Park SY; Shin KH; Kim DY; Kim JY
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):995-1002. PubMed ID: 15990000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of acute esophagitis in patients with non-small-cell lung carcinoma treated with concurrent chemotherapy and hyperfractionated radiotherapy followed by surgery.
    Patel AB; Edelman MJ; Kwok Y; Krasna MJ; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1106-12. PubMed ID: 15519781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric correlations of acute esophagitis in lung cancer patients treated with radiotherapy.
    Takeda K; Nemoto K; Saito H; Ogawa Y; Takai Y; Yamada S
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):626-9. PubMed ID: 15936536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer.
    Watkins JM; Wahlquist AE; Shirai K; Garrett-Mayer E; Aguero EG; Fortney JA; Sherman CA; Sharma AK
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1108-13. PubMed ID: 19084345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for acute esophagitis in non-small-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy.
    Wei X; Liu HH; Tucker SL; Liao Z; Hu C; Mohan R; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):100-7. PubMed ID: 16839700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and dosimetric risk factors of acute esophagitis in patients treated with 3-dimensional conformal radiotherapy for non-small-cell lung cancer.
    Zhang ZC; Xu J; Li BS; Zhou T; Lu J; Wang ZT; Li HS; Sun HF; Zhu J; Yu JM
    Am J Clin Oncol; 2010 Jun; 33(3):271-5. PubMed ID: 19823071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
    Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
    Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial.
    Pöttgen C; Eberhardt WE; Gauler T; Krbek T; Berkovic K; Jawad JA; Korfee S; Teschler H; Stamatis G; Stuschke M
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):809-15. PubMed ID: 19427744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute esophageal toxicity in non-small cell lung cancer patients after high dose conformal radiotherapy.
    Belderbos J; Heemsbergen W; Hoogeman M; Pengel K; Rossi M; Lebesque J
    Radiother Oncol; 2005 May; 75(2):157-64. PubMed ID: 15890421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.
    Marks LB; Garst J; Socinski MA; Sibley G; Blackstock AW; Herndon JE; Zhou S; Shafman T; Tisch A; Clough R; Yu X; Turrisi A; Anscher M; Crawford J; Rosenman J;
    J Clin Oncol; 2004 Nov; 22(21):4329-40. PubMed ID: 15514374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II study of synchronous three-dimensional conformal boost to the gross tumor volume for patients with unresectable Stage III non-small-cell lung cancer: results of Korean Radiation Oncology Group 0301 study.
    Cho KH; Ahn SJ; Pyo HR; Kim KS; Kim YC; Moon SH; Han JY; Kim HT; Koom WS; Lee JS
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1397-404. PubMed ID: 19117690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal tissue complication probability modeling for acute esophagitis in patients treated with conformal radiation therapy for non-small cell lung cancer.
    Chapet O; Kong FM; Lee JS; Hayman JA; Ten Haken RK
    Radiother Oncol; 2005 Nov; 77(2):176-81. PubMed ID: 16256230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
    Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).
    Wang S; Liao Z; Wei X; Liu HH; Tucker SL; Hu CS; Mohan R; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1399-407. PubMed ID: 16997503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
    Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
    J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
    Yom SS; Liao Z; Liu HH; Tucker SL; Hu CS; Wei X; Wang X; Wang S; Mohan R; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):94-102. PubMed ID: 17321067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for Stage IIIB non-small-cell lung cancer.
    Kim YS; Yoon SM; Choi EK; Yi BY; Kim JH; Ahn SD; Lee SW; Shin SS; Lee JS; Suh C; Kim SW; Kim DS; Kim WS; Park HJ; Park CI
    Int J Radiat Oncol Biol Phys; 2005 May; 62(1):76-81. PubMed ID: 15850905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy.
    Song CH; Pyo H; Moon SH; Kim TH; Kim DW; Cho KH
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):651-8. PubMed ID: 20207499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
    Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
    J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.